Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H A Peters

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2000
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study GroupM Salden, T A Splinter, H A Peters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Plasminogen activator inhibitor-1 and prognosis in primary breast cancerJ A Foekens, M Schmitt, W L van Putten, et al.
The New England Journal of Medicine|August 13, 1981
Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathyM E Tripp, M L Katcher, H A Peters, et al.
International Journal of Cancer|February 15, 1978
A new aspect of the urinary excretion of tryptophan metabolites in patients with cancer of the bladderF A Teulings, H A Peters, W C Hop, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 21, 2008
[Clinical reasoning and decision-making in practice. A man with hip pain and fever]P R Tuinman, L C F de Nes, J L G Blaauwgeers, et al.
Cancer Research|November 1, 1989
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosolsJ A Foekens, H Portengen, W L van Putten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Breast-conserving therapy: proteases as risk factors in relation to survival after local relapseM E Meijer-van Gelder, M P Look, J Bolt-de Vries, et al.
Breast Cancer Research and Treatment|December 1, 2001
Clinical relevance of biologic factors in male breast cancerM E Meijer-van Gelder, M P Look, J Bolt-de Vries, et al.
Cancer Research|April 1, 1995
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancerJ A Foekens, F Buessecker, H A Peters, et al.
International Journal of Cancer|June 17, 1998
Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cellsA M Sieuwerts, J G Klijn, S C Henzen-Logmand, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2000
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study GroupM Salden, T A Splinter, H A Peters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Plasminogen activator inhibitor-1 and prognosis in primary breast cancerJ A Foekens, M Schmitt, W L van Putten, et al.
The New England Journal of Medicine|August 13, 1981
Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathyM E Tripp, M L Katcher, H A Peters, et al.
International Journal of Cancer|February 15, 1978
A new aspect of the urinary excretion of tryptophan metabolites in patients with cancer of the bladderF A Teulings, H A Peters, W C Hop, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 21, 2008
[Clinical reasoning and decision-making in practice. A man with hip pain and fever]P R Tuinman, L C F de Nes, J L G Blaauwgeers, et al.
Cancer Research|November 1, 1989
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosolsJ A Foekens, H Portengen, W L van Putten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Breast-conserving therapy: proteases as risk factors in relation to survival after local relapseM E Meijer-van Gelder, M P Look, J Bolt-de Vries, et al.
Breast Cancer Research and Treatment|December 1, 2001
Clinical relevance of biologic factors in male breast cancerM E Meijer-van Gelder, M P Look, J Bolt-de Vries, et al.
Cancer Research|April 1, 1995
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancerJ A Foekens, F Buessecker, H A Peters, et al.
International Journal of Cancer|June 17, 1998
Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cellsA M Sieuwerts, J G Klijn, S C Henzen-Logmand, et al.
Pageof 7